13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
48 檔
63.7%
According to the latest 13F quarterly dataset, Artia Global Partners LP managed an equity portfolio of $541.9M at the end of Q3 2025, spanning 48 distinct U.S. exchange-listed positions.
In Q3 2025, Artia Global Partners LP displayed an active expansion posture, initiating 26 new positions and adding to 10 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 25.84% | -18.15% | +42.83% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 9.16% | +0.74% | — | |
| 3 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 7.20% | -0.46% | EXIT | |
| 4 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 6.41% | — | -62.70% | |
| 5 | QURE | uniQure N.V. | Stock-Other | 6.10% | — | — | |
| 6 | ✓ | Merus N V | Stock-Other | 4.43% | — | — | |
| 7 | UGL | Proshares Ultra Gold | ETF-Commodities | 3.92% | — | +219.86% | |
| 8 | LLY | Eli Lilly & Co | Stock-Healthcare | 3.47% | -7.04% | EXIT | |
| 9 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 3.42% | — | +1152.27% | |
| 10 | ABVX | Abivax Sa-adr | Stock-Other | 3.03% | -0.69% | — | |
| 11 | TRVI | Trevi Therapeutics Inc | Stock-Other | 2.90% | +2.80% | +52.43% | |
| 12 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.84% | — | +18.04% | |
| 13 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.50% | — | +64.85% | |
| 14 | DGX | Quest Diagnostics Inc | Stock-Healthcare | 2.47% | +0.95% | — | |
| 15 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.32% | — | — | |
| 16 | EYPT | Eyepoint Inc | Stock-Other | 1.42% | +0.04% | +98.41% | |
| 17 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.02% | — | +412.79% | |
| 18 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.95% | — | — | |
| 19 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.88% | -0.08% | +613.20% | |
| 20 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.77% | +3.98% | — | |
| 21 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.76% | — | +218.21% | |
| 22 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.68% | +0.19% | — | |
| 23 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.62% | -0.06% | — | |
| 24 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.61% | +0.12% | +51.51% | |
| 25 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.57% | +0.03% | -23.76% | |
| 26 | ABBV | Abbvie Inc | Stock-Healthcare | 0.53% | -0.63% | EXIT | |
| 27 | NKTR | Nektar Therapeutics | Stock-Other | 0.52% | — | — | |
| 28 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.51% | — | — | |
| 29 | ASND | Ascendis Pharma A/S | Stock-Other | 0.39% | -0.81% | EXIT | |
| 30 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.34% | -0.06% | +37.71% | |
| 31 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.33% | -0.09% | — | |
| 32 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.31% | — | — | |
| 33 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.30% | +0.20% | — | |
| 34 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.26% | — | — | |
| 35 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.25% | -0.04% | — | |
| 36 | IREN | IREN Limited | Stock-Other | 0.25% | — | — | |
| 37 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.24% | +0.04% | — | |
| 38 | BTSG | Brightspring Health Services | Stock-Other | 0.19% | +6.20% | — | |
| 39 | BHVN | Biohaven Ltd. | Stock-Other | 0.19% | — | — | |
| 40 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.18% | +0.06% | — | |
| 41 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.17% | -0.30% | EXIT | |
| 42 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.16% | — | — | |
| 43 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.14% | — | — | |
| 44 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.12% | +3.13% | — | |
| 45 | ATYR | Atyr Pharma Inc | Stock-Other | 0.11% | — | — | |
| 46 | MRNA | Moderna Inc | Stock-Healthcare | 0.10% | -2.03% | EXIT | |
| 47 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.08% | — | — | |
| 48 | ALEC | Alector Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +19.7% | +42.83% | Add |
| 2 | ARGX | Argenx Se - Adr | +7.5% | — | Add |
| 3 | EYPT | Eyepoint Inc | +1% | +98.41% | Add |
| 4 | ALNY | Alnylam Pharmaceuticals Inc | +0.6% | +64.85% | Add |
| 5 | 260 | Centessa Pharmaceuticals-adr | +0.4% | — | Add |
| 6 | ASND | Ascendis Pharma A/S | +0.1% | — | Add |
| 7 | VKTX | Viking Therapeutics Inc | +0.1% | +51.51% | Add |
| 8 | DGX | Quest Diagnostics Inc | 0% | — | Add |
| 9 | TVTX | Travere Therapeutics Inc | 0% | — | Unchanged |
| 10 | UTHR | United Therapeutics CORP | -0.1% | — | Unchanged |
| 11 | MREO | Mereo Biopharma Group Pl-adr | -0.1% | — | Add |
| 12 | ✓ | Merus N V | -0.1% | — | Trim |
| 13 | XENE | Xenon Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 14 | RVMD | Revolution Medicines Inc | -0.2% | — | Unchanged |
| 15 | TGTX | Tg Therapeutics Inc | -0.2% | — | Unchanged |
| 16 | BSX | Boston Scientific CORP | -0.5% | +18.04% | Add |
| 17 | SRRK | Scholar Rock Holding CORP | -0.8% | -23.76% | Trim |
| 18 | AZNN | Astrazeneca Plc-spons Adr | -1.2% | — | Unchanged |
| 19 | VRNA | Verona Pharma PLC - Adr | -2.2% | -62.70% | Trim |
| 20 | PTGX | Protagonist Therapeutics Inc | -3.9% | — | Trim |
| 21 | SLNOEUR | Soleno Therapeutics Inc | -6.1% | +35.95% | Trim |
| 22 | LLY | Eli Lilly & Co | -25.8% | -6.51% | Trim |
| 23 | QURE | uniQure N.V. | — | NEW | New buy |
| 24 | ITCIEUR | Intra-cellular Therapies Inc | — | EXIT | Sold out |
| 25 | UGL | Proshares Ultra Gold | — | NEW | New buy |
| 26 | VRTX | Vertex Pharmaceuticals Inc | — | NEW | New buy |
| 27 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 28 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 29 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 30 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 31 | NUVL | Nuvalent Inc-a | — | EXIT | Sold out |
| 32 | REGN | Regeneron Pharmaceuticals | — | NEW | New buy |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 34 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 35 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 36 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 37 | ABBV | Abbvie Inc | — | NEW | New buy |
| 38 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 39 | RYTM | Rhythm Pharmaceuticals Inc | — | EXIT | Sold out |
| 40 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
| 41 | VRDN | Viridian Therapeutics Inc | — | EXIT | Sold out |
| 42 | MLYS | Mineralys Therapeutics Inc | — | NEW | New buy |
| 43 | RAPP | Rapport Therapeutics Inc | — | NEW | New buy |
| 44 | ISRG | Intuitive Surgical Inc | — | EXIT | Sold out |
| 45 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 46 | NBIX | Neurocrine Biosciences Inc | — | EXIT | Sold out |
| 47 | IREN | IREN Limited | — | NEW | New buy |
| 48 | BTSG | Brightspring Health Services | — | NEW | New buy |
| 49 | BHVN | Biohaven Ltd. | — | NEW | New buy |
| 50 | KNSA | Kiniksa Pharmaceuticals International, plc | — | NEW | New buy |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 48 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, ARGX, SLNOEUR) accounted for 63.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
QURE
市值: $38.5M
Top Position Liquidated / Trimmed
ITCIEUR
前期市值: $29.0M
During Q3 2025, Artia Global Partners LP's top holdings by market value included INSM (25.8%)、ARGX (9.2%)、SLNOEUR (7.2%). The largest single position, INSM, represented 25.8% of total portfolio value.
In Q3 2025, Artia Global Partners LP made 52 total portfolio adjustments, initiating 26 new buys, adding to 10 positions, trimming 6 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.